King Pharmaceuticals, Inc. (KG)
The Company is a vertically integrated pharmaceutical company that develops, manufactures, markets and sells branded prescription pharmaceutical products.
Recs
Nzakanzaka
(< 20)
Submitted: 8/28/2009 12:46:43 AM :
Start Price:
$10.54
KG Score:
+7.75
With many drugs in the pipeline, this stock will either go much higher on its own, or it will be bought by the bigger boys. A nice place to park your money.
Recs
fooljh123457
(23.50)
Submitted: 8/17/2009 5:37:15 PM :
Start Price:
$10.43
KG Score:
+2.84
new technology they have fixed it to prevent abuse of over doing for affect. docs will be more likely to prefer this med over others that can be abused for recreation purposes. docs will flock to this med!
Recs
spotpetes
(75.32)
Submitted: 8/13/2009 3:18:11 PM :
Start Price:
$10.57
KG Score:
+4.17
Good looking company....
Recs
JohanHansen
(71.40)
Submitted: 8/5/2009 11:53:03 AM :
Start Price:
$9.34
KG Score:
+17.81
Chg to ST20 A 8/4
Recs
Recs
JMartinBlack
(68.96)
Submitted: 4/17/2009 4:15:13 PM :
Start Price:
$8.84
KG Score:
+5.75
King pharm has been performing well for me over the past month
Recs
adavisclan
(22.38)
Submitted: 2/18/2009 11:16:08 AM :
Start Price:
$8.35
KG Score:
+2.52
At 0.3, low debt to equity reducing risk in these tight money times. Forward P/E of 6.9x versus industry P/E of 10.8x. Price to sales of 1.0x versus industry of 2.4x. These numbers would seem to make KG an attractive take over target to a larger Pharma.
While two of King's Skelaxin patents have been invalidated and may result in a generic release, thier integration of AlphaPharma should more than offset any loss market in Skelaxin while also offering some synergistic cost savings.
Recs
YoungNGunnin
(87.58)
Submitted: 1/14/2009 11:54:13 AM :
Start Price:
$9.16
KG Score:
-1.67
Been heading south bound to head back up
Recs
Survivn2
(62.38)
Submitted: 10/16/2008 2:00:02 AM :
Start Price:
$7.99
KG Score:
+26.76
Pharma in rough times, MFI. Smaller cap than I wanted, but we'll give it a try.
Recs
RxIntern
(< 20)
Submitted: 9/6/2008 1:31:14 AM :
Start Price:
$11.99
KG Score:
+11.39
New Pain Meds = high profits!
Recs
oxsigtech
(< 20)
Submitted: 8/12/2008 9:50:44 AM :
Start Price:
$11.27
KG Score:
+19.12
They have had some rough times in the past, but these guys sell a lot of generic drugs.
Recs
Dragontoad2
(95.51)
Submitted: 7/2/2008 9:14:19 AM :
Start Price:
$10.50
KG Score:
+26.12
price/book =1.. solid numbers
Recs
NASAGeek
(95.31)
Submitted: 6/26/2008 9:21:56 PM :
Start Price:
$9.91
KG Score:
+32.54
magicformulainvesting.com screen at $153M market cap, top 25 companies on June 26, 2008
Recs
twistright
(< 20)
Submitted: 6/11/2008 7:38:25 PM :
Start Price:
$9.40
KG Score:
+42.83
increase in businesses offering fixed price prescriptions will boost near term demand for generics.
Recs
ResearchLover
(72.36)
Submitted: 6/4/2008 12:43:39 PM :
Start Price:
$10.02
KG Score:
+37.31
King pharmaceuticals has some products which generate great cash flow. It was supposed to weather the downturn better than it did. And now its discounted P/E reflects that.
Recs
angus118
(< 20)
Submitted: 5/22/2008 11:48:13 AM :
Start Price:
$9.85
KG Score:
+39.82
King Pharmaceuticals KG has been hurt by the loss of a patent dispute last year for the key ingredient in its hypertension drug Altace. The result has been generic competition for the drug much sooner than anticipated and this is having a negative effect on revenues and margins. As a result King has laid off 20% of its work and refocused its efforts on the neuroscience, hospital and acute care markets. The neuroscience division in particular could be very attractive should they receive FDA approval for their abuse resistant pain drug Remoxy. They hope to have the drug to market by 2009 and it is a potential blockbuster. The stock trades just off its 52-week lows and has a bulletproof balance sheet with over 60% of the stock price in cash. The EV/EBITDA ratio is just 1.5 and equally attractive to the asset-loving side of me, it trading at 85% of book value. It is worth a look at these levels. Tim Melvin - thestreet.com
Recs
noparking
(< 20)
Submitted: 5/14/2008 10:40:59 AM :
Start Price:
$9.70
KG Score:
+43.03
The King of... something.
Recs
Recs
tnlbohrer
(48.75)
Submitted: 5/2/2008 10:45:04 AM :
Start Price:
$9.74
KG Score:
+42.36
Buying low. Good Company with a wide variety of products.
Recs
keerthiprasad
(39.88)
Submitted: 4/28/2008 1:15:57 AM :
Start Price:
$9.11
KG Score:
+49.91
Currently trading below book value. Over half the market cap in CASH! This business is almost free at today's prices. Additionally, King will easily pull in over half a billion in cash this year. I agree that a catalyst to move the share price will be hard to find in the short term, but cheap is cheap. Value will be the catalyst in the long run.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 51 1 2 3 Next »